The effects of denosumab compared with alendronate on glucocorticoid-induced osteoporosis in patients with malignant lymphoma
Not Applicable
Recruiting
- Conditions
- glucocorticoid-induced osteoporosis in patients with malignant lymphoma
- Registration Number
- JPRN-UMIN000038881
- Lead Sponsor
- Toyama University Hospital Department of Hematology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with a history of hypersensitivity to any component of denosumab Patients with hypocalcemia Patients who are pregnant and who may be pregnant Patients with a condition that makes swallowing difficult such as stenosis and achalasia of esophagus Patients unable to sit upright or stand more than thirty minutes Patients with a history of hypersensitivity to bisphosphonates Patients with hypercalcemia or hypervitaminosis D Patients who are on osteoporotic treatment with denosumab or bisphosphonates Patients thought to be inappropriate for this study by physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method